Targets › TBXT
2 programs from 1 company in 3 trials: 2 Phase 2, 1 Phase 1; Oncology; next expected readout Jul 2027.
Involved in the transcriptional regulation of genes required for mesoderm formation and differentiation. Binds to a palindromic T site 5'-TTCACACCTAGGTGTGAA-3' DNA sequence and activates gene transcription when bound to such a site. (UniProt, O15178)
Open in Phaseline: the race on TBXT, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Adenovirus 5 CEA/MUC1/Brachyury Vaccine Tri-Ad5 Therapeutic cancer vaccine expressing CEA, MUC1, and Brachyury tumor-associated antigens | CEA, MUC1, TBXT | Phase 2 | Colorectal Carcinoma | Jul 2027 |
| National Cancer Institute (NCI) | Therapeutic CEA, Brachyury and MUC1 TriAdeno Vaccine Platform Adenoviral-based cancer vaccine targeting CEA, Brachyury and MUC1 | CEA, BRACHYURY, MUC1, KLK3, TBXT | Phase 2 | Adenocarcinoma; Metastatic Colorectal Cancer | Oct 2027 |
Adenocarcinoma (1) Metastatic Colorectal Cancer (1) Colorectal Carcinoma (1)
mixed (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.